Family Study of Lymphoproliferative Disorders
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT00626496
- Status
- Recruiting
Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Monoclonal B-Cell Lymphocytosis
- Multiple Myeloma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Accepted
Study Details
Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development of these cancers.
Key Dates
- Start date
- Apr 1, 2004
- Status verified
- Oct 2025
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 3,000 participants (estimated)
Primary Outcome Measure
Risk of blood or lymphoma [ Time Frame: Ongoing ]
Central Contacts
- Catie Erding1-855-899-0693
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | Susan L Slager, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
By condition
By specialty
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple MyelomaRecruiting · Center for International Blood and Marrow Transplant Research · Minneapolis, Minnesota
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersPHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota
- Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)PHASE1/PHASE2 · Recruiting · Juno Therapeutics, a Subsidiary of Celgene · Birmingham, Alabama